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Summary
Background Verrucae are a common foot skin pathology, which can in some cases
persist for many years. Plantar verrucae can be unsightly and painful. There are a
range of treatment options including needling.
Objectives The EVerT2 (Effective Verruca Treatments 2) trial aimed to evaluate the
clinical and cost-effectiveness of the needling procedure for the treatment of
plantar verrucae, relative to callus debridement.
Methods This single-centre randomized controlled trial recruited 60 participants
(aged ≥ 18 years with a plantar verruca). Participants were randomized 1 : 1 to
the intervention group (needling) or the control group (debridement of the
overlying callus). The primary outcome was clearance of the index verruca at
12 weeks after randomization. Secondary outcomes included recurrence of the
verruca, clearance of all verrucae, number of verrucae, size of the index verruca,
pain and participant satisfaction at 12 and 24 weeks. A cost-effectiveness analysis
was carried out from the National Health Service perspective over 12 weeks.
Results Sixty eligible patients were randomized (needling group n = 29, 48%;
debridement group n = 31, 52%) and 53 were included in the primary analysis
(needling n = 28, 97%; debridement n = 25, 81%). Clearance of the index ver-
ruca occurred in eight (15%) participants (needling n = 4, 14%; debridement
n = 4, 16%; P = 086). The needling intervention costs were on average £1433
(95% confidence interval 532–2335) more per patient than for debridement.
Conclusions There is no evidence that the needling technique is more clinically or
cost-effective than callus debridement. The results show a significant improve-
ment in pain outcomes after needling compared with the debridement treatment
alone.
What’s already known about this topic?
• Verrucae are notoriously difficult to treat, can last for many years and cause pain
and discomfort.
• There is a lack of high-quality evidence evaluating verruca treatments, and consid-
erable uncertainty regarding optimal treatments.
• Current common treatments of choice are salicylic acid and cryotherapy; however,
although both treatments are equally effective, the clearance rate for these treat-
ments is low (14%).
What does this study add?
• This trial evaluated the clinical and cost-effectiveness of a needling technique, rela-
tive to callus debridement.
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• There are two published studies on this treatment: a retrospective case series evalu-
ation and a small randomized controlled trial that reports needling to be more
effective than cryotherapy.
• This trial found no evidence to suggest that needling increases verruca clearance
rates.
• This trial provides evidence that needling significantly reduces pain compared with
callus debridement.
Plantar verrucae (or warts) are common, with prevalence rates
estimated between 084% (U.S.A.)1 and 129% (Russia).2 A
Cochrane systematic review of 21 trials for wart treatments
with placebo groups3 reported clearance rates that averaged
27% (range 0–73%) in the placebo groups after an average
period of 15 weeks (range 4–24). While these data have led
some practitioners to recommend that warts should not be
treated at all,4,5 patients often still seek treatment if verrucae
are unsightly or painful. There is uncertainty around the opti-
mal treatment of verrucae and a need for high-quality trials to
evaluate therapies.
The Falknor needling technique,6 first described in the
1960s, has recently received renewed interest as a treatment.
It involves administration of a local anaesthetic and repeatedly
inserting a needle into the verruca until it enters the underly-
ing dermis and subcutaneous fat layer. The mechanical trauma
to the viral tissue is believed to evoke inflammation and hence
enhance the immune response in the area.7 In a retrospective
review of 45 patients who received needling, 31 (69%) expe-
rienced clearance of verrucae, three (7%) demonstrated a
reduction in size and pain, and 11 (24%) showed no
improvement 8 weeks after treatment.8
To our knowledge, there is only one published randomized
controlled trial (RCT) evaluating the effectiveness of the need-
ling procedure.9 This trial randomized 37 participants to
receive either needling or cryotherapy. There was a statistically
significant difference in clearance of the primary verruca
12 weeks after the initial treatment: needling 65% (11 of 17)
and cryotherapy 6% (one of 16); P = 0 .001.
The objective of the EVerT2 (Effective Verruca Treatments
2) trial was to evaluate the clinical and cost-effectiveness of
the needling procedure compared with callus debridement for
the treatment of plantar verrucae.
Patients and methods
Trial design
Full details of the trial design have been published elsewhere10
and are provided in brief below. This was a single-centre,
pragmatic, open, two-armed RCT with an economic evalua-
tion. Ethical approval was obtained from the University of Sal-
ford, Department of Health Sciences Ethical Approval
Committee (HSCR15/24), and the University of York,
Department of Health Sciences Research Governance Commit-
tee (HSRGC/2014/98/B). The trial was registered with the
metaRegister of Controlled Trials (ISRCTN16429440).
Study population
Patients were eligible if they were aged ≥ 18 years and had a
plantar verruca on weight-bearing skin that, in the opinion of
the podiatrist, was suitable for both treatments. Potential par-
ticipants were excluded if they were unsuitable for local
anaesthesia, had impaired healing, were immunosuppressed
(or taking immunosuppressant drugs), had peripheral neu-
ropathy or renal failure requiring dialysis, were pregnant,
were unable or unwilling to give informed consent, or were
taking part in a trial evaluating other treatments for their ver-
ruca(e).
Recruitment and randomization of participants
Participants were recruited between March 2015 and March
2016 from the University of Salford Podiatry Clinic. Eligible
participants gave written informed consent and baseline
measures were taken. They were then randomized 1 : 1 to
receive needling or callus debridement immediately. A
member of the research team telephoned the secure, remote
randomization service at the York Trials Unit (YTU),
University of York, to obtain the allocation. Block random-
ization with randomly permuted block sizes of two and
four was used. The block size was kept secret from the
recruiting clinicians.
Interventions
Treatments were conducted by two podiatrists proficient in
the needling technique who received training in trial proce-
dures. For participants presenting with mosaic or multiple
plantar verrucae, the largest and thickest lesion (the index ver-
ruca) was identified.
Control group
The skin surrounding the index verruca was disinfected and
the callus overlying the lesion was removed using a surgical
blade.
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Intervention group: needling procedure
Intervention participants were treated as described for the con-
trol group, with the addition of the administration of a local
anaesthetic (Scandonest 3% plain) via tibial nerve block, prior
to callus debridement.
An empty surgical needle (21 gauge) was used repeatedly
to puncture through the lesion to the subcutaneous tissue to
produce point bleeding until there was no more resistance, or
reactive pressure, from the epidermis. This was done for the
whole lesion. The total number of punctures varied according
to the size of the lesion. In the case of large mosaic verrucae,
a section of the verruca was needled. This follows the practice
reported by Longhurst and Bristow.8 All participants were
asked not to take anti-inflammatory drugs (such as ibuprofen)
for 48 h but were permitted to take paracetamol for pain
relief.
Follow-up
Participants in the needling group attended a review appoint-
ment 1 week after the treatment, where debridement of any
uncomfortable eschar was performed. Participants completed
questionnaires at 1 day and 12 and 24 weeks and were
invited for follow-up appointments at 12 and 24 weeks after
randomization. At 12 weeks in both groups, overlying callus
was debrided if the lesion was causing discomfort. At
24 weeks, if the verruca had not cleared further, alternative
treatments were offered.
All participants received £20 of high-street shopping vouch-
ers, divided equally between the 12- and 24-week appoint-
ments, to offset any incidental expenses associated with trial
participation.
Outcome measures
Baseline assessment
Data on the participant and verruca were collected and a digi-
tal photograph of the verruca was taken (Appendix S1; see
Supporting Information).
Primary outcome
The primary outcome was clearance of the index verruca at
12 weeks after randomization as determined by blinded
assessment at the site. The podiatrist (blind assessor) was
asked what treatment they believed the participant had
received to assess the success of the blinded review.
Secondary outcomes
Clearance or recurrence of the treated verruca was assessed at
24 weeks. Secondary outcomes at 12 and 24 weeks included
time to clearance, clearance of all verrucae, number of verru-
cae, size of the index verruca, pain and participant satisfaction
with treatment. Data on pain and the use of painkillers 24 h
after treatment were collected.
Sample size
The EVerT2 trial was powered at 80% to detect a difference
in clearance rate of the index verruca from 30% in the
debridement group to 70% in the needling group at
12 weeks after randomization. Allowing for 10% attrition,
we required 58 participants to be randomized (29 to each
treatment group).
Statistical analysis
Analysis was conducted in Stata v13 (StataCorp, College Sta-
tion, TX, U.S.A.) using two-sided statistical tests at the 5%
significance level for the primary outcome and 1% for sec-
ondary outcomes. Available-case intention to treat was used
including all participants in the groups to which they were
randomized irrespectively of whether or not they received
their allocated treatment. Baseline and outcome data, includ-
ing adverse events, are summarized descriptively. The pri-
mary outcome was analysed using a v2-test. In a sensitivity
analysis, logistic regression was used to adjust the primary
analysis for duration of the verruca, whether or not the ver-
ruca had been previously treated and type of verruca (mo-
saic/nonmosaic). These analyses were repeated replacing any
missing blinded outcome data with self-reported clearance
where available. Clearance of all verrucae at 12 and
24 weeks, and clearance of the index verruca at 24 weeks,
were analysed via v2-tests.
Cohen’s kappa was used to measure the agreement of clear-
ance between the participant and the blinded assessor at 12
and 24 weeks. Poisson regression compared the number of
verrucae at 12 and 24 weeks between the treatment groups,
adjusting for the number of verrucae at baseline. Self-reported
time to clearance of all verrucae in days from randomization
was analysed using Cox proportional hazards regression
adjusting for duration of verruca, whether or not the verrucae
had been previously treated and type of verruca. Pain and size
of the index verruca at weeks 12 and 24 were analysed via
repeated measures covariance pattern models with baseline
value, treatment group, time and a treatment group-by-time
interaction term as fixed effects and participant as a random
effect.
Total costs per participant were calculated (including all
resource use and intervention costs) from the perspective of
the U.K. National Health Service (NHS). A multiple imputa-
tion approach was taken to account for missing data.
Results
Seventy-six individuals were screened and 61 (80%) were ran-
domized (Fig. 1). One ineligible participant (allocated to the
needling group) was randomized in error as they had a corn
and not a verruca. Therefore, 60 eligible patients were
© 2017 The Authors. British Journal of Dermatology
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randomized: 29 (48%) to the needling group and 31 (52%)
to the debridement group.
The majority of participants were female (n = 38, 63%),
and the mean age was 40 years (range 19–76) (Table 1). Par-
ticipants had had their verruca for a median of 3 years, and
most had sought treatment previously (n = 47, 78%). The
most commonly reported reason for seeking treatment was
that the verruca was painful (n = 42, 70%). In general, the
two groups were comparable at baseline; however, the pro-
portions of women, patients with a mosaic verruca and
patients who had sought previous treatment for their verrucae
were greater in the needling group than in the debridement
group, and the average pain experienced was higher.
All participants received their allocated treatment. Two par-
ticipants allocated to debridement withdrew from the trial:
one received debridement but later withdrew as they were not
happy with the treatment group they had been allocated to
and were not prepared to wait until after the trial to receive
needling; and one missed their 12-week review and withdrew
when invited for their 24-week appointment.
At 12 weeks, 53 (88%) participants had their index verruca
assessed for clearance by a blinded assessor (needling n = 28,
97%; debridement n = 25, 81%; Table S1; see Supporting
Information). Clearance of the index verruca was judged to
have occurred in eight (15%) participants [needling n = 4,
14%; debridement n = 4, 16%; difference in percentage 17,
Fig 1. CONSORT flow diagram of participants in the EVerT2 (Effective Verruca Treatments 2) trial. YTU, York Trials Unit.
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95% confidence interval (CI) 211–176, P = 086]. These
eight had complete clearance of all their verrucae (four partic-
ipants had one verruca at baseline; one each had two, three,
four or five). There was no evidence of a difference in the like-
lihood of clearance between the two groups from the v2-test
(v2 = 003, P = 086) or the adjusted logistic regression [odds
ratio (OR) 110, 95% CI 022–558, P = 091].
Two participants returned a 12-week participant question-
naire that included a self-assessment of clearance (both not
cleared) but did not return for a clinic assessment. There was
only a negligible difference in the parameter estimates and
P-values when the analyses were repeated replacing the missing
blinded outcome with self-reported clearance (results not pre-
sented). Of the eight participants with blinded assessed
Table 1 Baseline characteristics of randomized participants
Characteristic Needling (n = 29) Debridement (n = 31) Total (n = 60)
Age (years)
Mean  SD 425  142 371  129 397  137
Median (range) 404 (234–760) 365 (195–687) 381 (195–760)
Sex, n (%)
Male 9 (31) 13 (42) 22 (37)
Female 20 (69) 18 (58) 38 (63)
Number of verrucae at baseline
Mean  SD 40  32 42  38 41  35
Median (range) 3 (1–11) 3 (1–16) 3 (1–16)
Duration of verrucae (months)
Mean  SD 603  535 562  629 582  581
Median (range) 48 (3–240) 36 (6–312) 36 (3–312)
Type of verrucae, n (%)
Mosaic 5 (17) 3 (10) 8 (13)
Nonmosaic 24 (83) 28 (90) 52 (87)
Size of index verruca (mm2)
Mean  SD 519  782 617  1236 569  1034
Median (range) 22 (2–356) 18 (4–607) 205 (2–607)
Previous treatment, n (%)
Yes 25 (86) 22 (71) 47 (78)
No 4 (14) 9 (29) 13 (22)
Type of previous treatments, n (%)a
Over the counter 22 (76) 21 (68) 43 (72)
Podiatrist 18 (62) 14 (45) 32 (53)
General practitioner 9 (31) 7 (23) 16 (27)
Other trial 0 1 (3) 1 (2)
Otherb 6 (21) 1 (3) 7 (12)
Reason for seeking treatment, n (%)a
Pain 25 (86) 17 (55) 42 (70)
Unable to go swimming 10 (34) 9 (29) 19 (32)
Unable to participate in other sports 7 (24) 7 (23) 14 (23)
Otherc 10 (34) 14 (45) 24 (40)
Pain, visual analogue scale 0–100
Mean  SD 445  323 24  255 339  305
Median (range) 50 (0–96) 13 (0–83) 285 (0–96)
Previous verrucae, n (%) n = 25 n = 56
Yes 16 (64) 21 (68) 37 (66)
No 9 (36) 10 (32) 19 (34)
Number of previous verrucae n = 16 n = 21 n = 37
Mean  SD 44  50 47  65 45  58
Median (range) 2 (1–20) 3 (1–30) 2 (1–30)
Age at which previous verrucae occurred (years) n = 15 n = 22 n = 37
Mean  SD 279  210 185  92 223  156
Median (range) 23 (6–76) 165 (8–38) 18 (6–76)
Numbers of patients are given where data were unavailable for the full cohort. aMore than one category could be selected for each patient.
bSelf-filing/debridement (needling n = 3, debridement n = 1); duct tape (needling n = 2); hospital freeze treatment (needling n = 1).
cAesthetics (needling n = 5, debridement n = 4); concern about passing verruca to others (needling n = 1, debridement n = 5); had it so
long/want rid (needling n = 1, debridement n = 1); prevents from walking long distances (needling n = 2); invited to take part in EVerT2
trial (debridement n = 2); verruca getting worse/larger (needling n = 1, debridement n = 1); well-being (debridement n = 1).
© 2017 The Authors. British Journal of Dermatology
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clearance of all verrucae at 12 weeks, seven self-reported that
they believed their verrucae had cleared, while one did not.
Two further participants thought their verrucae had gone when
they had not. The level of agreement between self-reported and
blinded assessed clearance was high (j = 079, P < 0001).
At week 12, there was no evidence that the age of the ver-
ruca was associated with clearance (adjusted OR 10, 95% CI
098–102, P = 074). Also, verrucae that had been treated
previously were marginally less likely to clear than verrucae
that had not been treated before, but this difference was not
statistically significant (adjusted OR 08, 95% CI 012–528,
P = 081). All eight mosaic verrucae were still present at the
end of the 12-week period.
At week 12, the blinded podiatrists reported that they were
unable to tell which treatment the participant had received for
48 (91%) of the 53 participants assessed (needling 24 of 28,
86%; debridement 24 of 25, 96%). They believed that two
needling participants had received debridement, but correctly
identified the treatment for two needling participants and one
debridement participant.
At 24 weeks, 49 (82%) participants had their index verruca
assessed for clearance by a blinded assessor, and 11 of these
(22%) were judged to have cleared (needling five of 25, 20%;
debridement six of 24, 25%; v2 = 018, P = 068). All but
one of these had complete clearance of all verrucae (needling
five of 25, 20%; debridement five of 24, 21%; v2 = 001,
P = 094). Where both self-reported and blinded outcome
assessments of clearance were available, there was total agree-
ment (j = 100, P < 0001). One participant judged by the
blinded assessors to have complete clearance did not respond
to whether they thought their verrucae had all cleared, but
annotated the questionnaire with ‘Think it may have gone as
for the last 12 weeks I have had no pain. I found it difficult
to see the verruca position as it is in an awkward position’.
There were no reported instances of reoccurrence between
weeks 12 and 24.
The median number of verrucae at 12 weeks in the need-
ling group was 15 (range 0–8) (24 weeks, median 1, range
0–8) and in the debridement group it was 2 (range 0–19)
(24 weeks, median 1, range 0–11). There was no evidence of
a difference in the number of verrucae at 12 weeks [incidence
rate ratio (IRR) 089, 95% CI 067–118; P = 042)] or
24 weeks (IRR 081, 95% CI 050–131, P = 039) or in time
to clearance of all verrucae (hazard ratio 217, 95% CI 072–
654, P = 017) between the two groups.
Participants in the needling group reported higher levels of
pain at baseline and 1 day after treatment than in the debride-
ment group, but lower levels at 12 weeks, and also at
24 weeks when the difference was statistically significant
(Table 2). There was a small-to-moderate correlation between
pain and verruca size at 12 weeks (r = 037) and 24 weeks
(r = 015). Fifteen (26%) of the 57 participants who returned
a day 1 questionnaire reported using a painkiller after their
treatment (all in the needling group). There was no evidence
of a difference in the size of the index verruca between the
two groups at 12 or 24 weeks (Table 2).
More participants in the needling group than in the
debridement group said that they would be willing to have
the same treatment again (82% vs. 60%) (Table 3). Most of
the needling group at both 12 and 24 weeks were either
happy or very happy with their treatment, whereas in the
debridement group a greater number were indifferent,
unhappy or very unhappy than were happy or very happy.
There were two nonserious adverse events reported, both
unrelated to the trial and mild in intensity. One event was
expected (pain, needling participant) and one unexpected
(gastrointestinal tract yeast infection, needling participant).
Economic evaluation
All patients received at least one treatment visit at the podiatry
clinic. The mean number of treatment visits was similar
between groups: 214  074 for the needling group (n = 29)
vs. 196  054 for the debridement group (n = 31). Only one
participant in each group reported visiting a general practitioner
(GP) or nurse about their verrucae at the 12-week assessment.
Accounting for the total number of treatment visits to the podia-
try clinics, as well as additional GP/nurse visits, the needling
intervention cost on average £1433 (95% CI 532–2335) more
per patient compared with debridement.
Discussion
This is the largest trial to date evaluating the clinical and cost-
effectiveness of the needling technique. We found no evidence
of a difference in effectiveness between needling and callus
debridement in terms of clearance rates and verruca size, and
an increase in cost. However, although the pain 24 h after
treatment was greater in the needling group, the pain experi-
enced at 12 and 24 weeks was reduced for this group com-
pared with the callus debridement group. At 24 weeks this
difference was statistically significant. The needling technique
was found to be safe and acceptable to participants, and 82%
of the needling participants stated that they would be willing
to have the same treatment again. The needling treatment was
associated with higher costs per cured patient. There was no
difference in the likelihood of clearance between the two
groups, and the needling intervention has higher costs for no
additional benefit compared with debridement. Needling is
thus not cost-effective compared with debridement.
Our results for clearance conflict with the findings of the
only other RCT of the needling procedure by Cunningham
et al.9 This was a smaller study of 37 participants and showed
a statistically significant difference in clearance rates favouring
the needling group after 12 weeks, relative to cryotherapy.
The clearance rate for the needling group was 65% (11 of
17), which is approximately 45 times greater than our corre-
sponding rate of 14% (four of 28). Similarly, Longhurst and
Bristow8 reported a 69% (31 of 45) resolution of verrucae in
a retrospective case series analysis. However, our results are
similar to the EVerT trial, which reported a 14% cure rate for
both salicylic acid treatment and cryotherapy.11
© 2017 The Authors. British Journal of Dermatology
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Our study followed the same treatment protocols as Long-
hurst8 and Cunningham,9 with the exception that participants
in our needling group were given one treatment. Longhurst
and Bristow8 reported a high resolution rate (38 of 45) after
one needling treatment. Cunningham et al.9 reported a median
of 2 treatments, 5 weeks apart, and a mean of 161  005
treatments, 508  208 weeks apart. Cunningham et al.9 did
not report how many verrucae resolved after one or two treat-
ments. The theory that verrucae resolve in response to local-
ized tissue damage (which is yet to be confirmed) would
suggest that this could be achieved after one needling proce-
dure.
Data on resolution rates are unclear; therefore, if two treat-
ments are conducted within a few weeks of each other and
the verruca resolves it could be possible that the response
from the first treatment is still occurring when the second
treatment is administered. We therefore decided that from a
trial design perspective, one treatment in each group would
provide clarity in this regard. We also based our decision from
an ethical perspective, as if it is likely that the verrucae may
resolve after one treatment then it would not be ethical to
conduct a second treatment. As this is the first large RCT to
test the effects of needling on verrucae, we felt it necessary
to standardize the interventions between both groups. It is
possible that multiple treatments are required to stimulate the
required immune response and promote clearance, and this
may help explain the difference in results. The next step in
the evaluation of needling treatment would be to test the
number of treatments required to achieve verruca resolution.
Also, the use of combination treatments could be explored,
for example the use of home treatments between needling
treatments.
There are also differences between the populations in our
and Cunningham’s trials. The mean and median ages of the
Table 2 Verruca pain measured on a visual analogue scale, and verruca size (mm2) by randomized group and time point
Needling (n = 29) Debridement (n = 31) Adjusted mean difference (95% CI); P-value
How painful is your verruca today? 0 (no pain) to 100 (worst possible pain)
Baseline
Mean  SD 445  323 240  255
Median (range) 50 (0–96) 13 (0–83) –
Day 1 n = 28
Mean  SD 303  256 88  109
Median (range) 21 (0–89) 4 (0–36) –
Week 12 n = 26
Mean  SD 170  196 204  243 964 (2012 to 085); P = 007
Median (range) 4 (0–67) 6 (0–78)
Week 24 n = 24 n = 26
Mean  SD 109  170 155  219 1254 (2361 to 146); P = 003
Median (range) 4 (0–70) 5 (0–89)
Size of index verruca, mm2
Baseline
Mean  SD 519  782 617  1236
Median (range) 22 (2–356) 18 (4–607) –
Week 12 n = 28 n = 24
Mean  SD 383  690 508  996 010 (2061 to 2081); P = 099
Median (range) 11 (0–337) 125 (0–423)
Week 24 n = 24 n = 22
Mean  SD 463  916 190  337 279 (3402 to 2843); P = 086
Median (range) 125 (0–411) 85 (0–145)
Numbers of patients are given where patients had dropped out of the study or not provided data. CI, confidence interval.
Table 3 Participant satisfaction with treatment by randomized group
Needling
(n = 29)
Debridement
(n = 31)
Total
(n = 60)
Would you be willing to have the same treatment again?
Week 12, n (%) n = 28 n = 25 n = 53
Yes 23 (82) 15 (60) 38 (72)
No 2 (7) 9 (36) 11 (21)
Don’t know 3 (11) 1 (4) 4 (8)
How happy are you with your treatment?
Week 12, n (%) n = 29 n = 26 n = 55
Very happy 11 (38) 7 (27) 18 (33)
Happy 11 (38) 5 (19) 16 (29)
Neither happy
nor unhappy
5 (17) 7 (27) 12 (22)
Unhappy 0 7 (27) 7 (13)
Very unhappy 2 (7) 0 2 (4)
Week 24, n (%) n = 24 n = 26 n = 50
Very happy 9 (38) 7 (27) 16 (32)
Happy 7 (29) 4 (15) 11 (22)
Neither happy
nor unhappy
6 (25) 10 (38) 16 (32)
Unhappy 0 5 (19) 5 (10)
Very unhappy 2 (8) 0 2 (4)
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participants in our study (Table 1) are greater than those
reported by Cunningham et al.9 (mean 261  100 years,
median 225, range 18–53). Cunningham et al.9 recruited from
their university-based podiatry clinic only. However, in addi-
tion to recruiting from our university clinic, we advertised in
community areas accessed by the general public, such as super-
markets, health centres, day centres, leisure centres and athletics
clubs. We also placed advertisements in local newspapers and
via social media accounts. We can therefore accept that we
recruited from a wider population than the Cunningham study.
However, there is a general opinion within the podiatry profes-
sion (based on peer discussions and not evidence) that people
with tenacious verrucae opt for needling after all other treat-
ment options have been exhausted. Our data do show that the
majority of the participants (78%) had tried other treatments
before participating in the trial. Cunningham et al.9 did not
report data on previous treatments in their study.
Although overall the average verruca size at baseline was
similar in both trials (569 vs. 527 mm2), there is an imbal-
ance in verruca size in the Cunningham trial, and needling
participants tended to have much smaller verrucae (mean
291 mm2) than cryotherapy patients (750 mm2), which was
not accounted for in the analysis. In addition, our participants
tended to have had their verruca for longer than in the Cun-
ningham cohort (mean 58 vs. 34 months), with an even big-
ger difference seen in the two needling groups (60 vs.
29 months). Our data showed no association between the age
of the verruca and the clearance rate.
The major strength of this study is that it is of high quality.
The risk of bias has been minimized due to the use of ade-
quate randomization, allocation concealment, blinded outcome
assessment and intention-to-treat analysis. Our study does have
potential limitations. It was a single-centre study and therefore
the results may not be applicable to patients presenting in GP
practices, or NHS or private podiatry clinics.
This trial did not have a true placebo or ‘no treatment’ arm.
It was envisaged that people would volunteer for this study to
access the intervention treatment, which is not widely avail-
able in the NHS or private podiatry clinics. The risk of losing
participants to follow-up would have been high if these par-
ticipants were randomized into a ‘no treatment’ group. There-
fore, we decided to offer callus debridement (which is
currently the treatment provided in some NHS podiatry clin-
ics) to maximize participant retention throughout the trial. All
participants in the control group were offered a free needling
treatment at the end of the trial if their verruca was still pre-
sent. The use of a ‘sham’ needling treatment for the control
group was considered; however, the trial team concluded that
it would be unethical to administer a local anaesthetic if no
treatment was to be given. Therefore, it is likely that the clear-
ance we saw was due to natural history rather than any treat-
ment effects.
In summary, the results of this trial reveal that the verruca
needling treatment is no more efficacious than callus removal
and is more costly. The only significant result was in the pain
outcomes, which were reduced in the needling group com-
pared with the debridement group. The intervention was
dominated by usual care in the economic evaluation, hence it
is not cost-effective compared with usual care.
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